Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab for prevention of recurrent acute pancreatitis in severe hypertriglyceridemia
NL-OMON52186Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia comparing Evinacumab with Placebo (2 arms). Primary endpoint: Proportion of patients with at least 1 positively adjudicated acute pancreatitis episode during 52 weeks. Started Mar 2022; status: completed.
02
Drugs
evinacumab
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON52186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52186.